Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy

Thomas Powles; Michael Staehler; Börje Ljungberg; Karim Bensalah; Steven E Canfield; Saeed Dabestani; Rachel Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Alessandro Volpe; Axel Bex

doi:10.1016/j.eururo.2015.10.017

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy

Eur Urol. 2016 Jan;69(1):4-6. doi: 10.1016/j.eururo.2015.10.017. Epub 2015 Oct 24.

Authors

Thomas Powles¹, Michael Staehler², Börje Ljungberg³, Karim Bensalah⁴, Steven E Canfield⁵, Saeed Dabestani⁶, Rachel Giles⁷, Fabian Hofmann⁸, Milan Hora⁹, Markus A Kuczyk¹⁰, Thomas Lam¹¹, Lorenzo Marconi¹², Axel S Merseburger¹³, Alessandro Volpe¹⁴, Axel Bex¹⁵

Affiliations

¹ The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: Thomas.Powles@bartshealth.nhs.uk.
² Department of Urology, Ludwig-Maximilians University, Munich, Germany.
³ Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
⁴ Department of Urology, University of Rennes, Rennes, France.
⁵ Division of Urology, University of Texas Medical School at Houston, Houston, TX, USA.
⁶ Department of Urology, Skåne University Hospital, Malmö, Sweden.
⁷ Patient Advocate International Kidney Cancer Coalition (IKCC); University Medical Center Utrecht, Nephrology Department, Utrecht, The Netherlands.
⁸ Department of Urology, Sunderby Hospital, Sunderby, Sweden.
⁹ Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
¹⁰ Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
¹¹ Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
¹² Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
¹³ Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
¹⁴ Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
¹⁵ Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

PMID: 26508312
DOI: 10.1016/j.eururo.2015.10.017

Abstract

The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.

Publication types

Editorial

MeSH terms

Anilides / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Everolimus / therapeutic use
Humans
Kidney Neoplasms / drug therapy*
Nivolumab
Practice Guidelines as Topic*
Pyridines / therapeutic use*
Retreatment
Treatment Failure
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Anilides
Antibodies, Monoclonal
Antineoplastic Agents
Pyridines
Vascular Endothelial Growth Factor A
cabozantinib
Nivolumab
Everolimus